Lupin share price
NSE: LUPINBSE: 500257Pharmaceuticals & BiotechnologyMid Cap
Lupin Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1993 on BSE, Sep 2001 on NSE
Last close ₹1,989.90up ₹17.20 (0.87%)BSE ₹1,998.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,972.70.
29 Oct: open ₹1,977.40, high ₹1,999.60, low ₹1,962.30
52-week range of traded prices to 29 Oct 2026
₹1,892.90Low, 23 Oct 2026₹2,529.50High, 16 Jul 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹90,996 Cr105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.46
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 14.95
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.05
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 30.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 28.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,81,45154.5% delivered
About Lupin
Lupin Limited is a pharmaceutical company headquartered in Mumbai that makes branded and generic medicines, including complex generics (hard-to-make copies such as inhalers and injectables), biosimilars (close copies of biological medicines) and active pharmaceutical ingredients (a medicine's working substances).12 It sells in India, the United States, other developed markets and emerging markets, reaching patients through wholesalers, distributors and pharmacies and supplying hospitals and government health agencies.13
It serves patients in more than 100 countries and had 33 subsidiaries and a joint venture at the end of March 2026.45 In markets such as India, it has also expanded into diagnostics, digital health, neurorehabilitation and consumer healthcare.6 Its subsidiary Lupin Manufacturing Solutions, set up in 2023, develops and makes active ingredients for other drug companies under contract.7
The company was founded by Desh Bandhu Gupta and incorporated in 1983.48 On 1 Apr 2026 its Dutch subsidiary Nanomi completed the acquisition of VISUfarma, adding more than 60 branded eye-care products and a commercial presence in Italy, the United Kingdom, Spain, Germany and France.59 Manju D. Gupta chairs the board, Vinita Gupta is chief executive officer and Nilesh D. Gupta is managing director.10
Lupin key points
Results
- In the quarter to Jun 2026, revenue rose 32% to ₹8,277 crore and EBITDA (earnings before interest, tax, depreciation and amortisation) excluding foreign exchange and other income rose 50% to ₹2,464 crore, revenue above ₹8,000 crore and EBITDA above ₹2,400 crore for the first time.1112
- Lupin's net income after the minority shareholders' share was ₹14,150 million in the quarter to Jun 2026, up 16%, and its EBITDA margin excluding foreign exchange and other income was 30%, against 26.6%.1314
- In the year to Mar 2026, consolidated revenue from operations rose 23.1% to ₹279,580 million and reported EBITDA rose 68.6% to ₹92,405 million, a margin of 33.6% against 24.7%.1516
- Lupin's consolidated profit after tax in the year to Mar 2026 was ₹53,555 million, against ₹33,063 million, and its return on capital employed (operating profit as a share of the money invested in the business) was 28.4%, against 21.6%.17
Market position
- Rank by the measure the company states18
Item Mar 2026, May 2026 and Jun 2026 United States, by prescriptions in the quarter to Jun 2026 3rd Indian pharmaceutical market, by sales in the year to Jun 2026 8th Australian generics, by sales in the year to Mar 2026 4th South African generics, by sales in May 2026 7th - Its share of India's anti-tuberculosis medicine market rose to 64.1% in the year to Mar 2026, from 61.3% a year earlier.19
Where revenue comes from
Plants and capacity
- It has 15 manufacturing facilities across Asia, Europe and the Americas, which made 22,538 million formulation units (finished medicine units) and 3,372 tonnes of active ingredients in the year to Mar 2026.22
- Capital spending was about ₹25,231 million in the year to Mar 2026, on manufacturing reliability, injectable and inhalation platforms, digital systems and compliance.23
Research and development
- R&D spending was ₹608 crore in the quarter to Jun 2026, 7.4% of sales, against ₹498 crore and 8.1% a year earlier; its R&D team numbers more than 1,400 people.2425
- For the United States it has 50 first-to-file applications (first generic filings against a drug, which can earn sole generic sales for a time), 21 of them exclusive, and more than 45 injectable and 20 inhalation products in development.26
- Its first U.S. biosimilar, Armlupeg, was approved in the year to Mar 2026, and its ranibizumab biosimilar, Ranluspec, in the quarter to Jun 2026.2728
What the company expects
- On its earnings call of 7 Aug 2026, the company said it expects high single-digit revenue growth in the year to Mar 2027, with an EBITDA margin of around 25%; its finance chief later put the margin at 24% to 25%.2930
- On its earnings call of 7 Aug 2026, the company said it expects U.S. sales of $1.1 billion to $1.2 billion in the year to Mar 2027, as more rivals sell mirabegron and tolvaptan, and a return to U.S. growth the year after.31
- On its earnings call of 7 Aug 2026, the company said it expects to launch more than 50 U.S. products in the next 3 years, including 10 exclusive first-to-file products and 5 biosimilars.32
- The company said it expects its India formulations business to grow 1.2 to 1.3 times as fast as the Indian pharmaceutical market, and medicines for long-term conditions, about 67% of its India portfolio, to reach 70% within 5 years.3334
Recent events
- On 1 Oct 2026, Multicare Pharmaceuticals Philippines became wholly owned after buying back its last 30,559 minority shares; the holding of its subsidiary Nanomi had risen from 56.28% to 99.89% on 1 Jul 2026.3536
- On 28 Sep 2026, the company announced U.S. FDA tentative approval (cleared, but not yet free to sell) for its apixaban oral suspension, a liquid form of the blood thinner in Eliquis, to be made at Somerset, New Jersey.37
- On 31 Jul 2026, the company announced it had launched sugammadex injection in the United States after U.S. FDA approval; the drug reverses the muscle relaxants given during surgery.38
- On 20 Jul 2026, its U.S. subsidiary Lupin Inc. licensed 2 cancer drug programmes to Kaveri Therapeutics in exchange for an 82.2% equity stake.3940
Litigation and regulatory matters
- As of its presentation of 7 Aug 2026, Tarapur, Mandideep Unit-1 and Pithampur Unit-II were under remediation; the U.S. FDA rated Pithampur Unit II Official Action Indicated (findings needing regulatory action), and the company had submitted its response.4142
- In the quarter to Jun 2026, the U.S. FDA issued inspection reports with Voluntary Action Indicated status (findings that need no regulatory action) for its Ankleshwar and Somerset plants.42
Last updated
All 42 sources, each with its page
- 1. Exchange filing, 28 Sep 2026, page 2
- 2. Exchange filing, 31 Jul 2026, page 2
- 3. Annual report, 13 Jul 2026, page 289
- 4. Annual report, 13 Jul 2026, page 39
- 5. Annual report, 13 Jul 2026, page 243
- 6. Annual report, 13 Jul 2026, page 42
- 7. Annual report, 13 Jul 2026, page 89
- 8. Annual report, 13 Jul 2026, page 1
- 9. Annual report, 13 Jul 2026, page 81
- 10. Annual report, 13 Jul 2026, page 339
- 11. Earnings call, 7 Aug 2026, page 5
- 12. Earnings call, 7 Aug 2026, page 3
- 13. Investor presentation, 7 Aug 2026, page 5
- 14. Earnings call, 7 Aug 2026, page 7
- 15. Annual report, 13 Jul 2026, page 66
- 16. Annual report, 13 Jul 2026, page 115
- 17. Annual report, 13 Jul 2026, page 115
- 18. Investor presentation, 7 Aug 2026, page 15
- 19. Annual report, 13 Jul 2026, page 69
- 20. Investor presentation, 7 Aug 2026, page 7
- 21. Investor presentation, 7 Aug 2026, page 7
- 22. Annual report, 13 Jul 2026, page 122
- 23. Annual report, 13 Jul 2026, page 45
- 24. Earnings call, 7 Aug 2026, page 7
- 25. Annual report, 13 Jul 2026, page 52
- 26. Investor presentation, 7 Aug 2026, page 10
- 27. Annual report, 13 Jul 2026, page 42
- 28. Investor presentation, 7 Aug 2026, page 6
- 29. Earnings call, 7 Aug 2026, page 5
- 30. Earnings call, 7 Aug 2026, page 10
- 31. Earnings call, 7 Aug 2026, page 3
- 32. Earnings call, 7 Aug 2026, page 3
- 33. Earnings call, 7 Aug 2026, page 3
- 34. Earnings call, 7 Aug 2026, page 4
- 35. Exchange filing, 1 Oct 2026, page 1
- 36. Exchange filing, 1 Jul 2026, page 1
- 37. Exchange filing, 28 Sep 2026, page 2
- 38. Exchange filing, 31 Jul 2026, page 2
- 39. Exchange filing, 21 Jul 2026, page 1
- 40. Exchange filing, 21 Jul 2026, page 3
- 41. Investor presentation, 7 Aug 2026, page 11
- 42. Investor presentation, 7 Aug 2026, page 6
Results
Consolidated; ₹ crore.Lupin quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +28.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +49.5%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8,277 Crup 10.73%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1,417 Crdown 3.52%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 17.1%
Revenue by quarter
Peak revenue ₹8,277 Cr, quarter to Jun 2026; lowest ₹5,667 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 |
| Net profit | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 |
| Net margin | 15.2% | 14.9% | 13.8% | 19.5% | 21.1% | 16.5% | 19.6% | 17.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹27,958 Crup 23.12%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹5,355 Crup 61.98%
- Net margin
- 19.2%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 2 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2019, the company's revenue for that year, ₹16,369 Cr, differs from its quarters added, ₹16,638 Cr. From the year to Mar 2020, the company's revenue for that year, ₹15,375 Cr, differs from its quarters added, ₹16,393 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17,494 | 15,804 | 16,369 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 27,958 |
| Net profit | 2,563 | 251 | 615 | −270 | 1,228 | −1,509 | 448 | 1,936 | 3,306 | 5,355 |
| Net margin | 14.6% | 1.6% | 3.8% | – | 8.1% | −9.2% | 2.7% | 9.7% | 14.6% | 19.2% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2020: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- PharmaceuticalsPharmaceuticals, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹27,812 Crup 23.04%99.5%
- OthersOthers, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹147 Cr0.5%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the years to Mar 2019 and Mar 2020: days before it are of the company before the change.Lupin PE ratio and valuation
Price to earnings
At or below today's level on 2% of 744 trading days over the last 3 years.
LowestHighest
Its median30.95Industry median28.38
Price to book
At or below today's level on 61% of 1,981 trading days since Nov 2018.
LowestHighest
Its median3.58Industry median2.97
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 93% of 2,463 trading days over the last 10 years.
LowestHighest
Its median0.59%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +14.9% | +62.3% | −29.7% | 0.8% |
| 3 years | +53.4% | +131.1% | −33.9% | 0.6% |
| 5 years | +18.4% | +33.9% | −12.1% | 0.6% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2026.
Mutual fund holdings
248 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 122 of the 153 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 3 more funds filed their first portfolio on record, holding it.All 248 funds holding Lupin
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 5
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 5
- AddedAdded. Funds that held more shares than at the end of the month before.
- 89
- CutCut. Funds that held fewer shares than at the end of the month before.
- 64
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 82
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 HDFC Balanced Advantage FundHDFC Mutual Fund | 56,86,457 | 1.13% | ₹1,154.5 Cr |
| HDFC Flexi Cap FundHDFC Mutual Fund | 48,88,886 | 0.91% | ₹992.5 Cr |
| HDFC Large Cap FundHDFC Mutual Fund | 46,15,980 | 2.51% | ₹937.1 Cr |
 Mirae Asset Large & Midcap FundMirae Asset Mutual Fund | 39,39,111 | 1.87% | ₹799.7 Cr |
| Mirae Asset Midcap FundMirae Asset Mutual Fund | 32,18,048 | 3.34% | ₹653.3 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 27,83,991 | 6.17% | ₹565.2 Cr |
| Nippon India Growth Mid Cap FundNippon India Mutual Fund | 22,00,000 | 0.89% | ₹446.6 Cr |
 Kotak Arbitrage FundKotak Mahindra Mutual Fund | 21,93,850 | 0.59% | ₹445.4 Cr |
 SBI Midcap FundSBI Mutual Fund | 21,00,000 | 1.83% | ₹426.3 Cr |
| Nippon India Large Cap FundNippon India Mutual Fund | 19,78,374 | 0.78% | ₹401.6 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Lupin insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade
- Others: no market trade · 2 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Lupin competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Lupin in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Dr. Reddy's LaboratoriesDRREDDY | 1,12,264 | 40.10 | 2.89 | −3.5% | −51.5% | 7.5% | 6.0% | 0.59% |
 CiplaCIPLA | 1,09,709 | 37.87 | 3.10 | −0.7% | −46.8% | 8.5% | 9.7% | 0.96% |
 Mankind PharmaMANKIND | 1,01,993 | 45.36 | 5.80 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 95,507 | 25.73 | 2.52 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 Glenmark PharmaceuticalsGLENMARK | 66,012 | 36.72 | 6.28 | +32.9% | +138.4% | 18.6% | 39.8% | 0.11% |
 Alkem LaboratoriesALKEM | 60,727 | 28.15 | 4.39 | +13.4% | −5.6% | 16.7% | 16.5% | 1.04% |
 BioconBIOCON | 57,349 | 115.79 | 1.69 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
 Abbott IndiaABBOTINDIA | 55,556 | 34.41 | 11.64 | +6.3% | +11.2% | 35.9% | 39.6% | 2.51% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Lupin dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹18.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 17 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹18.00 |
| 25 Jul 2025 | Final | ₹12.00 |
| 16 Jul 2024 | Final | ₹8.00 |
| 14 Jul 2023 | Final | ₹4.00 |
| 14 Jul 2022 | Final | ₹4.00 |
| 27 Jul 2021 | Final | ₹6.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Lupin announcements
Oct 2026
24 Oct · General Updates
23 Oct · Disclosure
22 Oct · Management
19 Oct · Disclosure
19 Oct · Analysts
Lupin share price by year
Each calendar year to 2025.Lupin share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,109.50 | −10.5% | 2,396.10 | 1,851.80 |
| 2024 | 2,355.70 | +78.1% | 2,355.70 | 1,312.85 |
| 2023 | 1,322.95 | +80.3% | 1,339.95 | 640.00 |
| 2022 | 733.70 | −22.8% | 959.45 | 590.25 |
| 2021 | 950.75 | −2.7% | 1,247.25 | 858.25 |
| 2020 | 976.85 | +28.0% | 1,085.90 | 548.10 |
| 2019 | 763.45 | −9.6% | 883.10 | 667.60 |
| 2018 | 844.30 | −4.6% | 968.75 | 734.50 |
| 2017 | 885.10 | −40.5% | 1,521.75 | 808.95 |
| 2016 | 1,486.95 | −19.1% | 1,905.65 | 1,398.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 1,954.00 | 1,974.00 | 1,935.00 | 1,972.70 | 1,962.13 | 3,70,876 | 51.9% |
| 27 Oct 2026 | 1,949.00 | 1,966.60 | 1,942.40 | 1,952.00 | 1,954.59 | 6,57,952 | 61.1% |
| 26 Oct 2026 | 1,928.00 | 1,959.90 | 1,912.40 | 1,959.90 | 1,935.74 | 4,45,630 | 51.8% |
| 23 Oct 2026 | 1,922.00 | 1,929.90 | 1,892.90 | 1,928.90 | 1,912.68 | 7,02,156 | 55.7% |
| 22 Oct 2026 | 1,942.00 | 1,945.70 | 1,896.10 | 1,922.00 | 1,920.85 | 7,28,620 | 54.6% |
| 21 Oct 2026 | 1,948.10 | 1,964.00 | 1,929.00 | 1,964.00 | 1,945.03 | 6,33,221 | 60.5% |
| 19 Oct 2026 | 1,955.80 | 1,971.60 | 1,930.00 | 1,939.20 | 1,953.77 | 6,02,008 | 56.4% |
| 16 Oct 2026 | 1,980.00 | 1,980.50 | 1,947.00 | 1,961.60 | 1,961.21 | 7,29,311 | 63.4% |
| 15 Oct 2026 | 1,943.00 | 1,990.90 | 1,943.00 | 1,980.90 | 1,974.82 | 6,73,280 | 53.6% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 27 Aug 2010 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- LUPIN
- BSE code
- 500257
- ISIN
- INE326A01037
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.lupin.com
- CIN
- L24100MH1983PLC029442
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1983
- Registered office
- Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai 400055, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In BSE 100, Nifty 200, BSE 200, Nifty 500, BSE 500, Nifty Midcap 150